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Persistent hepatitis C virus infection is associated with pro-
gressive hepatic fibrosis and liver cancer. Acute infection evokes
several distinct innate immune responses, but these are partially
or completely countered by the virus. Hepatitis C virus proteins
serve dual functions in replication and immune evasion, act-
ing to disrupt cellular signaling pathways leading to inter-
feron synthesis, subvert Jak-STAT signaling to limit expres-
sion of interferon-stimulated genes, and block antiviral
activities of interferon-stimulated genes. The net effect is a
multilayered evasion of innate immunity, which negatively
influences the subsequent development of antigen-specific
adaptive immunity, thereby contributing to virus persistence
and resistance to therapy.
Hepatitis C virus (HCV)2 is a small, hepatotropic, positive-
strand RNA virus classified within a unique genus of the Flavi-
viridae family (1). Its genome is 10 kb in length and encodes
only 10 different proteins (Fig. 1), yet HCV is able to survive the
immune response in most acutely infected persons and estab-
lish lifelong persistent infection. Such chronic infections are
associatedwith a significant risk of progressive liver fibrosis and
hepatocellular carcinoma.Worldwide,130million people are
persistently infected with HCV, resulting in an estimated
366,000 deaths due to cirrhosis and cancer annually (2). HCV is
thus a significant public health threat. It is also difficult and
expensive to treat. Current standard-of-care therapies combine
pegylated interferon- (Peg-IFN-) and ribavirin but cure
50% of patients with genotype 1 virus infection. Direct-acting
specific antiviral therapies are on the near horizon but will be
limited by rapid selection of resistant virus unless administered
as part of a multidrug mixture (3). Peg-IFN- is thus likely to
remain a mainstay of therapy for years to come.
Antigen-specific adaptive T cell immunity is key to deter-
mining the outcome of acuteHCV infection, with virus-specific
CD4 T cell help essential for effective T cell control (reviewed
in Ref. 4). However, earlier innate immune responses are also
critical. They are induced upon host recognition of common
molecular patterns expressed by HCV and other viruses, and
they provide relatively immediate protection against infection.
IFNs play a central role in the innate immune response to
viruses and comprisemultiple classes of soluble cytokines, each
with a distinct receptor system. Those of known relevance to
HCV include type I IFNs (IFN- and over a dozen distinct
IFN- subtypes, encoded by genes clustering on human chro-
mosome 9), type II IFN (IFN-, a single IFN type encoded by a
gene on chromosome 12), and type III IFN (IFN-, three sub-
types known otherwise as interleukin (IL)-29, IL-28A, and
IL-28B) (5, 6). Overlapping signaling pathways induce the
expression of type I and III IFNs, and this occurs in many types
of cells infected with viruses. In turn, these IFNs induce similar
if not identical antiviral states in cells, albeit through different
receptors with distinct cell-type distributions. IFN- is mark-
edly different. Its production is restricted to certain types of
immune cells, such as natural killer cells and cytotoxic T cells,
and its actions are primarily immunomodulatory.
Sequence polymorphisms in human genes encoding IFN-3
(IL-28B) (7), IFN- (8), and the natural killer cell receptor
KIR2DL3 and its human leukocyte antigen C group 1 ligand (9)
influence the outcome of HCV infection. The association
between outcome and IFN-3 genotype is particularly strong
and also evident in the response to Peg-IFN- therapy (10).
These genome-wide association studies provide clinical evi-
dence of the close linkage that exists between the innate and
adaptive immune responses. Type I IFN regulation of compo-
nents of the class I antigen processing pathway, including PA28
(proteasome activator 28) subunits and endoplasmic reticulum
aminopeptidases (11), is one example of such linkage. IFN-3
regulation of regulatory T cells is another (12). There are
undoubtedly many others (13).
IFN Signaling in the Liver
IFN-stimulated genes (ISGs) are expressed at high levels in
the liver in many patients with chronic hepatitis C and indeed
are induced within 48 h of acute infection in chimpanzees (14–
16). However, other chronically infected patients show little or
no evidence of ISG expression in the liver (16), despite similar
levels and duration of virus infection. At present, there is no
good understanding of this or the activation status of the innate
immune signaling pathways and transcription factors control-
ling IFN synthesis within infected and uninfected cells in the
HCV-infected liver.
IRF3 (IFN regulatory factor 3), a highly regulated transcrip-
tion factor constitutively expressed in the cytoplasm in a latent
inactive form, plays a key role in regulating the synthesis of
IFN- (17). Virus infections typically induce specific C-termi-
nal phosphorylation of IRF3, resulting in its dimerization and
transport to the nucleus. In coordination with NF-B and
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ATF2/c-Jun, IRF3 forms an enhanceosome complex on the
IFN- promoter, leading to transcriptional activation and syn-
thesis of IFN- (18). Secreted IFN- binds the type I IFN-/
receptor (IFNAR), resulting in autocrine/paracrine activation
of the Jak (Janus kinase)-STAT (signal transducer and activator
of transcription) signaling pathway, which leads in turn to the
expression of many dozens of ISGs controlled by promoters
containing IFN-stimulated response elements. IRF7 synthesis
is similarly induced and is capable of forming heterodimers
with IRF3; its role as an amplifier is critical to the induction of
most IFN- genes (19). Activated IRF3 is also capable of
directly inducing the transcription of a subset of ISGs, some
of which (like ISG56) have direct antiviral activity against HCV
(20, 21). IRF3 also controls transcription of IFN- (22).
IRF3 is activated by cell receptors that sense “pathogen-asso-
ciated molecular patterns” (PAMPs) residing in viral proteins
and RNAs. Defining HCV-specific PAMPs and the receptors
they bind in the liver has been a daunting task, as available
experimental systems are generally poor mimics of conditions
in vivo. Wild-type virus does not replicate well in cell culture,
and there are no good small animal models of hepatitis C.
Nonetheless, studies in cell culture indicate that two distinct
PAMP receptors, retinoic acid-inducible gene I (RIG-I) (23, 24)
and TLR3 (Toll-like receptor 3) (25), sense HCV infection,
induce IFN- promoter activity, and partially restrict viral rep-
lication. Both of these PAMP receptors recognize viral RNAs.
TLR2 may also sense infection, inducing inflammatory signals
upon binding HCV proteins (26). A fourth potentially impor-
tant sensor is TLR7. Little is known specifically about its role in
the induction of IFN responses in theHCV-infected liver, but it
is a likely player. Although they act to some extent redundantly,
these receptors differ in terms of the PAMPs they sense, where
they are expressedwithin the cell, andwhether they are likely to
be expressed in hepatocytes infectedwithHCV.They also differ
in their utilization of signaling adaptor proteins, two of which
are targeted for degradation by HCV.
RIG-I Signaling in HCV Infection
RIG-I (DDX58) is a DExD box helicase expressed ubiqui-
tously within the cytoplasm of most cell types. It senses short
non-self double-stranded RNAs (dsRNAs) with free 5-triphos-
phates (Fig. 2, left) (27, 28). Ligand recognition is dependent
upon an ATP-driven translocase activity (29) and results in the
recruitment of RIG-I to the mitochondrial surface, where it
interacts with MAVS (mitochondrial antiviral signaling pro-
tein; also known as IPS-1, VISA, and Cardif) resident on the
outer mitochondrial membrane (30–32). This occurs through
shared caspase recruitment domains (CARDs) in RIG-I and
MAVS. Tandem CARDs near the N terminus of RIG-I become
accessible upon RNA binding, inducing a conformational
change relieving the effect of a C-terminal regulatory domain
(33). This promotes RIG-I self-association as well as interac-
tionswith theMAVS adaptor, leading to assembly of a signaling
complex on the mitochondrial surface that activates down-
stream non-canonical kinases of the IB kinase complex,
TBK-1 (TANK-binding kinase 1) and IB kinase-, that phos-
phorylate IRF3 (34).
A complete discussion of RIG-I signaling is well beyond the
scope of this minireview, but a considerable number of host
proteins are essential for optimal induction of IFN- synthesis
via this pathway (Fig. 2, left). The RING finger domain-contain-
ing E3 ubiquitin ligase TRIM25 (tripartite motif-containing
protein 25) mediates ubiquitylation of RIG-I at Lys-63, and this
is essential for efficientMAVS binding and downstream induc-
tion of IFN synthesis (35). TRAF3 (tumor necrosis factor recep-
tor-associated factor 3) is also required for optimal IFN induc-
tion, interacting with MAVS and helping to link it to the
downstream kinases responsible for IRF3 phosphorylation (36,
37). TRAF6 is also recruited to the MAVS complex and, along
with MEKK1, a member of the MAP3K family, is required for
optimal activation of NF-B, an essential component of the
IFN- enhanceosome (18, 38). TRADD, a tumor necrosis factor
receptor adaptor protein, is also recruited to MAVS and has
been implicated in IRF3 andNF-B activation (39). NF-B acti-
vation involves an interaction with CARD9 (CARD family
member 9) andBcl-10 (B cell CLL/lymphoma10) protein that is
MAVS-dependent but not required for IRF3 activation (Fig. 2,
left) (40). On the other hand, NLRX1, a conserved nucleotide-
binding domain and leucine-rich repeat-containing family
member, is localized to the mitochondrial outer membrane,
where it interacts with MAVS and may negatively regulate sig-
naling (41).
Upstream of MAVS, RIG-I interacts with ASC (apoptosis-
associated speck-like protein containing CARD; PYCARD)
(Fig. 2, left), linking RIG-I sensing of viral RNA toMAVS-inde-
pendent activation of a caspase-1-dependent inflammasome
(40). Inflammasome-mediated production of mature IL-1 is
influenced by signaling through MAVS, as it is dependent
upon NF-B-mediated stimulation of pro-IL-1 expression.
Although IL-1 expression occurs in the context of viral hepa-
titis, it is not known if hepatocytes (the cell type within which
HCV replicates) are capable of mounting an inflammasome
response.
RIG-I senses infection by many RNA virus types, including
those with positive- and negative-strand as well as double-
stranded genomes (42). Picornaviruses are an exception, as
their RNAs lack a free 5-triphosphate and are sensed by a
related CARD-containing helicase, MDA5 (melanoma differ-
entiation-associated gene 5) (42). RIG-I is functionally ex-
pressed within hepatocytes and most hepatocyte-derived cell
lines (43, 44). It senses HCV infection in Huh-7 hepatoma cells,
leading to transient nuclear translocation of IRF3 and activa-
tion of the IFN- promoter (23). Hydrodynamic transfection of
FIGURE 1. Organization of the positive-sense RNA genome of HCV.
Genomic RNA contains a single large open reading frame flanked by 5- and
3-untranslated RNA segments. The open reading frame encodes a polypro-
tein of 3000 amino acids that undergoes processing by cellular and viral
proteases to produce 10 mature proteins. The core (C) and envelope proteins
E1 and E2 are structural components of the infectious virus particle, whereas
the remaining proteins are nonstructural (NS) and required for RNA replica-
tion (NS3–NS5B) or particle assembly and egress from the cell (p7 and NS2).
Major viral protease activities include NS2, which cleaves in cis at the NS2-NS3
junction, and NS3/4A, a noncovalent complex of the N-terminal domain of
NS3 and an accessory peptide sequence from NS4A that directs cleavage at
the sites indicated by the red arrowheads and also targets the cellular signal-
ing proteins MAVS and TRIF for proteolysis.
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synthetic HCV RNAs has shown that a conserved poly(U/C)
sequence from the 3-untranslated RNA segment of the HCV
genome stimulates ISG expression in mouse liver, where it is
recognized by RIG-I, presumably in conjunction with
5-triphosphate, as an HCV PAMP (43).
Prior to the identification of RIG-I, the major protease
expressed by HCV, NS3/4A, was found to inhibit Sendai virus-
induced activation of the IFN- promoter in cells containing
self-amplifying HCV replicon RNAs (45). This was shown sub-
sequently to be due to NS3/4A-mediated cleavage of the RIG-I
adaptor protein MAVS (32, 46). Scission occurs between Cys-
508 and His-509, close to the C terminus of MAVS, releasing
MAVS from the mitochondrial membrane and eliminating its
ability to function in signaling (Fig. 2, left). Oligomerization of
MAVS is essential to its ability to signal; this occurs through its
mitochondrial transmembrane domain and is blocked by
NS3/4A cleavage (47). Although RIG-I has been shown to rec-
ognize HCV infection in Huh-7 cells, signaling is shut down as
infection progresses, NS3/4A accumulates, and MAVS is
degraded (23). This can be reversed by ketoamide and macro-
cyclic peptidomimetic inhibitors of NS3/4A now being devel-
oped as potential therapies for hepatitis C but only at concen-
trations significantly greater than the antiviral EC50 (48). Why
higher drug concentrations are required for restoration of sig-
naling is unknown. It is possible that
HCV infection impacts signaling at
another step in the pathway (49).
The NS3 protein, a component of
NS3/4A, interacts directly with
TBK-1, and this may add to the dis-
ruption of IRF3 activation (50).
Overexpression studies suggest that
another HCV nonstructural pro-
tein, NS4B, may also interfere with
RIG-I signaling (51), but the reliabil-
ity of this experimental approach is
questionable.
There is little doubt that HCV
functionally disrupts RIG-I signal-
ing in vivo. Although infection is
limited to a minority of hepatocytes
(52), immunoblots show MAVS to
be cleaved in liver biopsies from
some patients with chronic hepati-
tis C (23). This suggests that the
intrahepatic IFN responses ob-
served in many patients (16) either
are induced through alternative sig-
naling pathways or possibly origi-
nate in newly infected cells that have
yet to accumulate sufficientNS3/4A
to ablate signaling. The cleavage of
MAVS by NS3/4A is likely to con-
tribute to HCV pathogenesis, but it
is not unique or a proximate cause
of virus persistence. The protease of
a closely related flavivirus, GB virus
B, also cleaves MAVS, yet this virus
typically causes self-limited infection in its natural hosts (53). In
addition, the 3ABCprotease precursor expressed by hepatitis A
virus, a picornavirus associated only with acute hepatitis in
humans, is targeted to the mitochondrial membrane, where it
also cleaves MAVS with similar effects on signal transduction
(54).
TLR3 Signaling in Hepatitis C
TLR3 senses dsRNA formed during the replication of posi-
tive-strand RNA viruses as well as some DNA viruses (55). A
membrane-bound protein, it is expressed predominantly in an
early endosomal compartment, where it senses extracellular
ligand (56). Structural models suggest that dsRNA complexes
40–50 bp in length bind sites at opposite ends of a horseshoe-
shaped ectodomain containing leucine-rich repeats (57). This
drives dimerization of TLR3, which initiates signaling through
its cytosolic TIR (Toll/IL-1 receptor homology) domain. TLR3
dimerization results in recruitment of an adaptor protein, TRIF
(TIR domain-containing adaptor-inducing IFN-; also known
asTICAM-1), that interactswithTLR3 throughhomotypicTIR
domains (Fig. 2, right) (58, 59). This interaction is transient,
after which TRIF relocates to distinct punctate cytoplasmic
bodies, possibly as an oligomer (56). At some point in this pro-
cess, TRAF6, TRAF3, and TBK-1 are recruited to TRIF, leading
FIGURE 2. RIG-I and TLR3 sensing of viral RNAs induces IFN- synthesis. Two distinct signaling pathways,
one initiated by the recognition of 5-triphosphate-containing cytosolic viral RNAs by the DExD box helicase
RIG-I (left) and the other by TLR3 recognition of viral dsRNA 40 –50 bp within the lumen of vesicles in an early
endosomal compartment (right), lead to phosphorylation of IRF3, activation of NF-B, and induction of IFN-
transcription. Both pathways are disrupted by expression of the viral NS3/4A protease, which cleaves the
adaptor proteins MAVS and TRIF, respectively. See text for details. In addition to those proteins shown, roles
have been suggested for MEKK1, FADD, and RIP in RIG-I signaling leading to IFN- synthesis. TM, transmem-
brane domain; PI3K, phosphatidylinositol 3-kinase; IKK, IB kinase; MITA, mediator of IRF3 activation.
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to phosphorylation of IRF3 (37, 58). Endosomal acidification is
required for recognition of dsRNA by TLR3 (60), and phosphor-
ylation of TLR3 by phosphatidylinositol 3-kinase is essential for
full activationof IRF3and inductionof IFN- synthesis (61).TLR3
ligation of dsRNA also strongly induces NF-B activity and pro-
inflammatory cytokine synthesis via interactions of TRIF with
RIP-1 (receptor-interacting protein 1) kinase (58, 62).
TLR3 is expressed in a variety of cell types in the liver, includ-
ing stellate cells, resident macrophages (Kupffer cells), myeloid
dendritic cells, and biliary epithelial cells (63). It is expressed at
low levels in normal hepatocytes but can be demonstrated
directly in uninfected human liver by two-photon microscopy
(25, 64). Primary cultures of human hepatocytes strongly up-
regulate expression of ISGs, including TLR3 itself, when stim-
ulated by extracellular poly(I:C), a dsRNA surrogate (25, 65).
The impact of HCV on TLR3 signaling has been difficult to
study because Huh-7 hepatoma cells that are commonly used
for propagation of HCV do not express TLR3 (44). This may be
because TLR3 expression is regulated by p53, which is mutated
in Huh-7 and many other hepatocellular carcinoma cell lines.
However, TLR3-mediated poly(I:C) stimulation of IRF3- and
NF-B-responsive promoters is inhibited in HeLa cells con-
taining a replicating subgenomic HCV replicon RNA, as well as
in HCV-infected Huh-7.5 cells in which TLR3 expression was
reconstituted by retroviral gene transduction (Huh7.5-TLR3
cells) (25, 66). TLR3 signaling was also disrupted in osteosar-
coma cells conditionally expressing NS3/4A but could be par-
tially restored following treatment with a specific NS3/4A pro-
tease inhibitor (66). TRIF is cleaved in vitro by NS3/4A (Fig. 2,
right), and its expression is significantly reduced in HeLa cells
containing HCV replicons or in Huh-7.5 cells infected with
HCV (25, 66). Brief treatment of infected cells with an NS3/4A
inhibitor partially restores TRIF expression (25). In some cell
types, however, NS3/4A overexpression has been reported not
to reduce TRIF abundance (65, 67). This may reflect cell type-
specific differences in TRIF orNS3/4A localization or technical
difficulties assessing TRIF abundance, as it is normally
expressed at very low levels.
NS3/4A-mediated cleavage of TRIF occurs at a unique site in
the molecule bearing remarkable sequence homology to the
NS4B/5A cleavage site in the viral polyprotein (66, 68).
Whereas sites of NS3/4A scission in the polyprotein have an
acidic residue at the P6 position, the P6 position in TRIFmarks
the end of an extended polyproline tract that likely assumes a
left-handed polyproline II helical conformation (68). A peptide
substrate containing this polyproline sequence is nonetheless
processed efficiently by the protease (66, 68). NMR studies sug-
gest that the polyproline II helix in TRIF may associate with a
310 helix near the NS3 catalytic triad, anchoring the substrate
and promoting its cleavage (68).
TLR3 senses HCV infection and induces ISG expression in
Huh7.5-TLR3 cells that are deficient in RIG-I signaling (25).
This partially restricts HCV replication when cells are infected
at low multiplicity, but the protective effect is overwhelmed by
a high multiplicity of infection. Unlike RIG-I, TLR3 can poten-
tially sense viral dsRNA released by other cells into the extra-
cellular milieu. Because NS3/4A is expressed only within
infected cells, TLR3-mediated responses in uninfected hepato-
cytes and other cell types may contribute to IFN responses
observed in some patients.
HCV Infection and Other TLRs
TLR2 senses bacterial and fungal cell wall components or
viral structural proteins and induces expression of pro-inflam-
matory cytokines when bound by ligand (69). Expressed on the
plasmamembrane of monocytes and other cell types, including
hepatocytes (63), it acts cooperatively with TLR1 or TLR6 to
signal via a TRIF- and MAVS-independent pathway involving
sequential recruitment of the adaptor proteins TIRAP (TIR
domain-containing adaptor protein) and MyD88 (myeloid dif-
ferentiation factor 88). Downstream signaling involves IL-1
receptor-associated kinases (IRAKs) and TRAF6, resulting in
activation of NF-B. TLR2 signaling is stimulated in primary
human monocytes and macrophages by recombinant HCV
core and NS3 protein, inducing synthesis of tumor necrosis
factor- and IL-10 (26). Whether this occurs in vivo is
unknown, but TLR2 signaling could contribute to inflamma-
tory changes in the HCV-infected liver. TLR2 also signals from
an endosomal location in inflammatory monocytes (a discrete
population of Ly6CCD11bCD11c cells in bone marrow
and spleen), inducing IRF3 activation and type I IFN synthesis
in response to viral ligands (70).Whether such cells exist within
the liver or would sense HCV infection is not known. Overex-
pression studies suggest that the viral NS5A protein may inter-
act with MyD88, preventing the recruitment of IRAK and
inhibiting TLR signaling (71), but the biological relevance of
this is uncertain, as evidence that HCV infects monocytes or
macrophages is lacking.
TLR7 is expressed by plasmacytoid dendritic cells (pDCs),
which can produce 200–1000-fold more type I IFN than any
other type of cell in the blood (72). TLR7 senses single-
stranded RNA within an endosomal compartment, signaling
via MyD88, TRAF6, and IRAK-4 to activate IRF7, which is
constitutively expressed at high abundance in pDCs.
BDCA3 pDCs are abundant within some HCV-infected liv-
ers (73), and it seems likely that TLR7 signaling in such cells
may be a source of IFN in patients with strong ISG responses.
Consistent with this, pDCs are triggered to produce type I
IFN through a TLR7-dependent pathway when co-cultured
with Huh-7 cells containing replicating HCV RNA (74). Data
concerning the influence of HCV infection on pDC function
in vivo are conflicting (75, 76).
TLR7 is also expressed at low level in hepatocytes (77). Con-
sistent with this, a potent TLR7 agonist induced an antiviral
response in Huh-7 cells containing replicating HCV RNA (77).
A G/U-rich single-stranded 20-nucleotide sequence from the
polyprotein-coding region of the HCV genome, as well as a
poly(U) sequence from the 3-untranslated RNA, stimulated
production of IFN- when transfected into pDCs and also
induced NF-B activation in Huh-7 cells (78). These segments
of the HCV genome appear to function as PAMPs, but it is not
certain that the response observed in Huh-7 cells wasmediated
by TLR7. HCV infection did not induce NF-B activation in
Huh-7 cells in this study (78), but Huh-7 cells typically display
high basal NF-B activity. It is not knownwhether HCV specif-
ically disrupts TLR7 signaling.
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IFN-induced Intracellular Signaling
Type I IFN- and IFN- mediate gene transcription by sig-
naling in a paracrine and autocrine fashion after binding the
heterodimeric IFNAR on the plasma membrane (Fig. 3). Over-
expression of the HCV core protein interferes with IFN signal-
ing downstream of the IFNAR, most likely because of a direct
interaction with STAT1, leading to reduced phospho-STAT1
(Fig. 3) (79, 80). However, although HCV protein expression
impaired downstream IFN signaling in transgenic mice, tyro-
sine phosphorylation of STAT proteins by Jak was not affected
(81). PP2A (protein phosphatase 2A) was up-regulated in these
animals, perhaps as a result of endoplasmic reticulum stress
(82, 83). This was associated with reduced methylation of
STAT1, presumably due to direct inhibition of PRMT1 (protein
arginine methyltransferase 1) by PP2A (82, 84). Hypomethyla-
tion of STAT1 promotes its association with PIAS1 (protein
inhibitor of activated STAT1), a negative regulator of STAT1-
mediated gene transcription (Fig. 3). The finding of reduced
arginine methylation of STAT1 and increased STAT1-PIAS1
association in HCV-infected human liver tissues provides sup-
port for this mechanism in vivo (82, 84).
Clinical data indicate that enhanced expression of SOCS3
(suppressor of cytokine signaling 3) within the HCV-infected
liver is associated with poor treatment outcome and thus may
impede Jak-STAT signaling (80, 85). On the other hand, recent
studies implicate USP18 (ubiquitin-specific peptidase 18; or
UBP43) rather than SOCS1 or SOCS3 in long-term refractori-
ness to IFN in mice dosed repeatedly with IFN- (86). This
situation may mimic that in many untreated hepatitis C
patients, in which there may be persistent stimulation of type I
IFN expression. In addition to its ISG15-deconjugating activity,
USP18 interacts with the IFNAR2 subunit of the IFNAR and
may thus act to suppress Jak-STAT signaling induced by type I
IFNs (87). RNA interference-mediated silencing of USP18
potentiates the antiviral activity of IFN- against HCV in cell
culture (88). Importantly, USP18 gene expression is increased
in the livers of many HCV-infected patients and is associated
with poor response to Peg-IFN- therapy (15, 16). In summary,
Jak-STAT signaling initiated by IFN-/ appears likely to
be suppressed in HCV infection, possibly through multiple
mechanisms.
Type III IFNs bind a distinct heterodimeric membrane
receptor composed of IL-10R2 and IFNLR1 subunits but utilize
the same Jak-STAT signaling pathway downstream involving
Jak-1 and Tyk-2 to activate gene transcription (Fig. 3) (6). IFN-
-induced signaling is thus subject to the same potential sup-
pression by PP2A and SOCS3 as IFN-/ but would not be
affected by the interaction of USP18 with IFNAR2 (87).
Interference with IFN Effector Mechanisms
In addition to interfering with the induction of IFN synthesis
and IFN-induced intracellular signaling, HCV may specifically
target IFN-induced effector mechanisms. NS5A (and possibly
also the envelope protein E2) binds to and antagonizes the
dsRNA-activated kinase protein kinase R (PKR) (89–91). An
inducible ISG, PKR regulates cellular translation through
dsRNA-stimulated autophosphorylation and subsequent phos-
phorylation of the translation initiation factor eIF2. Although
the viral internal ribosome entry site controlling translation of
the HCV polyprotein is relatively insensitive to phospho-PKR
and phospho-eIF2 (92), PKR nonetheless negatively regulates
HCV replication non-cytolytically in cultured cells (93, 94). The
activation of PKR by HCV impairs ISG protein expression in
cell culture, as it causes a general repression of translation, and
it has been suggested that this may paradoxically impede the
antiviral actions of IFN (95). It is not clear, however, that such a
mechanism would be operative in vivo or consistent with con-
tinued survival of infected hepatocytes.
NS5A also interacts with 2,5-oligoadenylate synthetase,
potentially interfering with its activity (96). Data indicating an
association between sequence polymorphisms in NS5A and
treatment outcome support a role for NS5A in IFN antagonism
in vivo (97). Transgenicmice expressingNS5A also showdefec-
tive PKR, IFN-, and 2,5-oligoadenylate synthetase responses
to virus infection and are slow in clearing adenovirus from the
liver due to impaired IFN- expression (98, 99). It is possible
that enhanced intrahepatic expression of USP18 (15, 16) could
also blunt IFN responses through its ISG15-deconjugating
activity (100).
FIGURE 3. Suppression of IFN-induced Jak-STAT signaling in hepatitis C.
Type I (IFN-/) and III (IFN-) IFNs initiate signaling by binding to distinct
heterodimeric receptors on the plasma membrane but then signal
through a common pathway involving Tyk-2 and Jak-1 phosphorylation of
STAT1 and STAT2 and subsequent recruitment of IRF9 to form the tran-
scription factor ISGF3, which stimulates transcription of ISGs under the
control of IFN-stimulated response elements. The HCV core protein may
confound these responses by interacting directly with STAT1, whereas
endoplasmic reticulum stress within infected cells may induce PP2A activ-
ity that acts indirectly through PRMT1 and PIAS to suppress signaling.
Type I IFN signaling may also be impeded by induction of USP18 that
interacts directly with the IFNAR2 subunit of the IFNAR. See text for details.
ISRE, IFN-stimulated response element.
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Conclusions
HCV infection evokes a number of innate immune re-
sponses, many of which are partially or completely countered
by the virus. Reflecting successful adaptation to its human host,
HCV has evolved mechanisms that disrupt signaling pathways
involved in the induction of IFN synthesis, subvert Jak-STAT
signaling to limit the expression of ISGs, or directly block the
antiviral activities of some ISGs. The net effect is amultilayered
evasion of innate immune responses, which is likely to exert a
profound negative influence on the subsequent development of
adaptive immunity to HCV, contributing to virus persistence
and resistance to therapy.
Acknowledgments—I thankKui Li andZongdi Feng for critical review
of the manuscript.
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